Investigational drug · Phase 3
PF-06838435
Also called: fidanacogene elaparvovec
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Hemophilia B.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "PF-06838435"
First trial start
2019
Jul 29, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PF-06838435", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hemophilia B
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "PF-06838435" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of Factor IX Gene Therapy With PF-06838435 in Adult Males With Moderately Severe to Severe Hemophilia BPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT03861273 · 51 participants · Start Jul 29, 2019 · Primary completion Nov 16, 2022
Drug: PF-06838435/ fidanacogene elaparvovec · For: Hemophilia B
Sites: San Francisco, California; Aurora, Colorado; Indianapolis, Indiana · 65 sites in all
PfizerPfizer (PFE)
NCT03307980 · 21 participants · Start Jun 22, 2017 · Primary completion Jul 23, 2026
Drug: PF-06838435 (formerly SPK-9001) · For: Hemophilia B
Sites: Sacramento, California; Metairie, Louisiana; New Orleans, Louisiana · 25 sites in all
PfizerPfizer (PFE)
NCT02484092 · 15 participants · Start Nov 18, 2015 · Primary completion Apr 8, 2019
Drug: SPK-9001 · For: Hemophilia B
Sites: Sacramento, California; Jackson, Mississippi; Madison, Mississippi · 10 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Future directions and challenges of drug development and non-human primate models.
Wang Z, Wu X · Life Sci 2026
- Adeno-associated virus gene therapy for hemophilia B: a comparative appraisal of the licensed products.
Miesbach W, Pierce GF · Haematologica 2026
- Patient-Relevant Questions on Gene Therapy for Haemophilia.
Miesbach W, Alberio L, Angelilo-Scherrer A, et al. · Hamostaseologie 2026
- Bridging the Gap: A Systematic Review of Modern Hemophilia Therapies and Global Inequities in Clinical Trial Participation.
Afifah NN, Permatasari LI, Latarissa IR, et al. · Haemophilia 2026
- Arthroplasty After Hemophilia Gene Therapy: Perioperative Implications and Clinical Experience.
Vu DN, Nguyen TT, Pham TN, et al. · Haemophilia 2026
- Fidanacogene Elaparvovec Gene Therapy: Budesonide Treatment of a Late Decline in Factor IX Expression in a Patient with Hemophilia B.
Herbst K, Pezeshkpoor B, Klein C, et al. · Int J Mol Sci 2026
Also in development for Hemophilia B
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Pfizer.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.